Cat. No. 2386
Chemical Name: N-(3-Chlorophenyl)-N'-(4,5-dihydro-1
Biological ActivityPotent and selective non-competitive mGlu5 antagonist that displays inverse agonist properties; blocks mGlu5 constitutive activity in vitro (IC50 = 87 nM). Acts at an allosteric modulatory site shared with MPEP and binds the mGlu5 receptor with Kd values of 54 and 31 nM for rat and human receptors respectively. Displays anxiolytic activity following oral administration in vivo; also exhibits analgesic properties.
The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.
All Tocris products are intended for laboratory research use only.
Certificate of Analysis / Safety Data Sheet
Montana et al (2009) The metabotropic glutamate receptor subtype 5 antagonist fenobam is analgesic and has improved in vivo selectivity compared with the prototypical antagonist 2-methyl-6-(phenylethynyl)-pyridine. J.Pharmacol.Exp.Ther. 330 834. PMID: 19515968.
Porter et al (2005) Description of a clinically validated anxiolytic with mGlu5 antagonist properties. Neuropharmacology 49 (Suppl. 1) 267.
Porter et al (2005) Fenobam: a clinically validated nonbenzodiazepine anxiolytic is a potent, selective, and noncompetitive mGlu5 receptor antagonist with inverse agonist activity. J.Pharmacol.Exp.Ther. 315 711. PMID: 16040814.
If you know of a relevant reference for this product please let us know.
Citations are publications that use Tocris products.
Do you know of a great paper that uses Fenobam from Tocris? If so please let us know.
View Related Products by Target
View Related Products by Product Action
Keywords: Fenobam, supplier, Potent, selective, mGlu5, antagonist, mGluR5, antagonists, Group, I, Receptors, Glutamate, Metabotropic, Tocris Bioscience, Glutamate (Metabotropic) Group I Receptor Antagonist products
Find multiple products by catalog number
New Products in this Area
Negative allosteric modulator at mGlu7; brain penetrantVU 0409551
Selective mGlu5 positive allosteric modulator; brain penetrant and orally bioavailable
October 30 - November 3, 2016
Boston, MA, USA